Jiangsu Nhwa Pharmaceutical Co., LTD (SHE: 002262)

Jiangsu Nhwa Pharmaceutical Co., LTD Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	1,546	2,159	1,532	1,608	1,402	1,821
Short-Term Investments	-	-	-	-	-	90
Trading Asset Securities	2,300	1,335	1,452	1,058	837	70
Cash & Short-Term Investments	3,846	3,494	2,984	2,666	2,239	1,981
Cash Growth	13.33%	17.08%	11.94%	19.05%	13.06%	34.12%
Accounts Receivable	1,302	1,054	843.93	720.49	609.22	610.48
Other Receivables	66.44	41.84	42.52	27.61	19.35	27.47
Receivables	1,368	1,095	886.45	748.09	628.57	637.95
Inventory	660.87	628.64	716.34	604.33	433.86	345.48
Prepaid Expenses	-	0	0	4.81	-	-
Other Current Assets	52.35	36.63	63.4	19.96	17.73	39.21
Total Current Assets	5,928	5,255	4,650	4,043	3,320	3,003
Property, Plant & Equipment	1,483	1,496	1,304	1,158	1,034	898.96
Long-Term Investments	108.1	106.77	118.61	130.41	81.23	50.38
Other Intangible Assets	230.35	190.47	111.1	95.98	101.04	106.19
Long-Term Deferred Tax Assets	45.19	58.32	36.95	30.66	31.2	20.8
Long-Term Deferred Charges	201.06	128.03	131.88	80.51	25.95	3.83
Other Long-Term Assets	133.23	94.05	128.51	158.09	155.18	117.9
Total Assets	8,129	7,328	6,481	5,697	4,748	4,202
Accounts Payable	432	277.2	255.74	267.17	165.19	127.55
Accrued Expenses	-	296.13	297.36	53.09	38.73	26.45
Short-Term Debt	65	55	30	38	38	38
Current Portion of Leases	20.65	20.86	20.63	25.01	-	-
Current Income Taxes Payable	177.1	84.1	83.5	80.85	97.91	93.62
Current Unearned Revenue	31.73	26.49	26.7	24.11	41.07	-
Other Current Liabilities	202.81	54.26	80.02	193.72	194.05	230.3
Total Current Liabilities	929.29	814.03	793.94	681.96	574.95	515.92
Long-Term Debt	0.23	0.23	0.23	0.23	0.23	0.23
Long-Term Leases	28.36	35.56	41.91	47.67	-	-
Long-Term Unearned Revenue	53.87	53.87	58.05	63.6	67.77	80.53
Long-Term Deferred Tax Liabilities	-	1.46	3.3	-	-	-
Other Long-Term Liabilities	12.95	12.95	-	-	-	-
Total Liabilities	1,025	918.09	897.43	793.45	642.94	596.68
Common Stock	1,016	1,008	1,008	1,008	1,008	1,019
Additional Paid-In Capital	193.25	102.99	119.41	119.41	49.85	154.75
Retained Earnings	6,014	5,317	4,481	3,783	3,086	2,509
Treasury Stock	-98.86	-	-	-	-35.32	-64.44
Comprehensive Income & Other	6.75	6.75	13.1	10.95	15.09	2.35
Total Common Equity	7,132	6,434	5,622	4,921	4,123	3,621
Minority Interest	-27.6	-24.03	-37.79	-16.96	-17.5	-15.86
Shareholders' Equity	7,104	6,410	5,584	4,904	4,105	3,605
Total Liabilities & Equity	8,129	7,328	6,481	5,697	4,748	4,202
Total Debt	114.24	111.64	92.77	110.91	38.23	38.23
Net Cash (Debt)	3,732	3,382	2,891	2,555	2,201	1,943
Net Cash Growth	12.60%	16.98%	13.16%	16.08%	13.31%	67.57%
Net Cash Per Share	3.70	3.36	2.86	2.53	2.17	1.93
Filing Date Shares Outstanding	1,001	1,008	1,008	1,008	1,008	1,019
Total Common Shares Outstanding	1,001	1,008	1,008	1,008	1,008	1,019
Working Capital	4,998	4,441	3,856	3,361	2,745	2,488
Book Value Per Share	7.12	6.39	5.58	4.88	4.09	3.55
Tangible Book Value	6,901	6,244	5,510	4,825	4,022	3,514
Tangible Book Value Per Share	6.89	6.20	5.47	4.79	3.99	3.45
Buildings	-	599.08	593.38	569.55	604.46	410.41
Machinery	-	1,341	1,251	1,088	934.72	853.78
Construction In Progress	-	293.76	92.07	17.21	3.7	60.88

Source: S&P Capital IQ. Standard template. Financial Sources.